CONSUMER MEDICINE INFORMATION LEAFLET

Similar documents
CONSUMER MEDICINE INFORMATION LEAFLET

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

1 WHAT OCTAGAM 50 mg/ml IS AND WHAT IT IS USED FOR

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin

1. What Panzyga is and what it is used for

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

INTRATECT 100 g/l solution for infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. Intratect 50 g/l solution for infusion. Human normal immunoglobulin (IVIg)

JvD/PL/ PACKAGE LEAFLET

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins

Before you are given Privigen

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Privigen solution for infusion

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

NEW ZEALAND DATA SHEET

PATIENT LEAFLET: INFORMATION FOR THE USER. SUBCUVIA 160 g/l Solution for Injection Human Normal Immunoglobulin

Package leaflet: Information for the user. Privigen 100 mg/ml (10%) solution for infusion Human normal immunoglobulin (IVIg)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Gamunex 10% 100 mg/ml solution for infusion Human normal immunoglobulin (IVIg)

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER

IMOJEV Japanese encephalitis vaccine (live, attenuated)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate

Package leaflet: Information for the user

Human plasma protein 50 mg/ml of which at least 96% is IgG, with a content of antibodies to Hepatitis B virus surface antigen (HBs) of 50 IU/ml

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

เอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)

Some general information on hepatitis A infection is given at the end of this leaflet.

(English translation of official Dutch version) PACKAGE LEAFLET JK/PL/

Flebogamma 5% DIF Human normal immunoglobulin (IVIg) 50 mg/ml - Solution for infusion.

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

Ig VENA 50 g/l Solution for infusion Human normal immunoglobulin (IVIg) for intravenous use

Elements for a Public Summary

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - 1 -

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

PACKAGE LEAFLET: INFORMATION FOR THE USER. AVAXIM, Suspension for injection in a pre-filled syringe Hepatitis A vaccine (inactivated, adsorbed)

Package leaflet: Information for the user. KIOVIG 100 mg/ml solution for infusion Human normal immunoglobulin

PACKAGE LEAFLET: INFORMATION FOR THE USER

Information for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print

IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe

1 What Engerix B is and what it is used for

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

FluQuadri ; FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion)

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Cuvitru 200 mg/ml solution for subcutaneous injection Human normal immunoglobulin

PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES. Lubiprostone

HERNOVIR 200 mg tablets

Package Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER. Raloxifen STADA 60 mg film-coated tablets (raloxifene hydrochloride)

PACKAGE LEAFLET: INFORMATION FOR THE USER Alfuzosin Sandoz 5 mg, prolonged-release tablets. Alfuzosin hydrochloride

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

Package leaflet: Information for the user. Ezetimibe STADA 10 mg, tabletten. Ezetimibe

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

Elements for a Public Summary

1. What Faslodex is and what it is used for

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

VAQTA Adult, Suspension for injection

PACKAGE LEAFLET: INFORMATION FOR THE USER

1. What Miacalcic is and what it is used for

Package leaflet: Information for the user Priorix, powder and solvent for solution for injection in a pre-filled syringe

PACKAGE LEAFLET: INFORMATION FOR THE USER. GRAZAX 75,000 SQ-T oral lyophilisate

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

Eloxatin Oxaliplatin concentrated solution for injection

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

PATIENT INFORMATION LEAFLET

MENACTRA Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Perjeta Contains the active ingredient pertuzumab (rch)

TREANA 5mg and 10mg Film-coated Tablets

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)

PACKAGE LEAFLET: INFORMATION FOR THE USER

Normal Immunoglobulin (Human), 10% for Intravenous or Subcutaneous Administration

Each vial of 48 ml contains: 8 g of human normal immunoglobulin.

Your treatment with XELJANZ

PACKAGE LEAFLET: INFORMATION FOR THE USER. ZADITEN 1 mg/5 ml Oral Solution. Ketotifen (as Ketotifen hydrogen fumarate)

Package leaflet: Information for patient

1. What Octostim Nasal Spray is and what it is used for

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone

SUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

Package leaflet: Information for the patient

Package Leaflet: Information for the User

PACKAGE LEAFLET Package leaflet: Information for the user. Ranitidin Actavis 150 mg and 300 mg film-coated tablets. Ranitidine

Transcription:

CONSUMER MEDICINE INFORMATION LEAFLET Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Flebogamma 10% DIF is and what it is used for 2. Before you use Flebogamma 10% DIF 3. How to use Flebogamma 10% DIF 4. Possible side effects 5. How to store Flebogamma 10% DIF 6. Further information 1. WHAT FLEBOGAMMA 10% DIF IS AND WHAT IT IS USED FOR What Flebogamma 10% DIF is Flebogamma 10% DIF is a solution for intravenous infusion containing 100 g/l human normal immunoglobulin. Flebogamma 10% DIF is one of the group of medicines called intravenous immunoglobulins. These are used to treat conditions where the body s defence system against disease is not working properly. What Flebogamma 10% DIF is used for Treatment of patients who do not have sufficient antibodies (replacement therapy): Primary Immunodeficiency (PI) Diseases Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. Treatment of patients with certain inflammatory disorders (immunomodulation): Idiopathic Thrombocytopaenic Purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count. Guillain Barré syndrome. It is used to treat Kawasaki disease, an illness in children where the blood vessels (arteries) in the body become enlarged. If you have any question about use of Flebogamma 10% DIF please ask your doctor. 1

2. BEFORE YOU USE FLEBOGAMMA 10% DIF Do not use Flebogamma 10% DIF - If you are allergic (hypersensitive) to human normal immunoglobulin or any of the other ingredients of Flebogamma 10% DIF (see special warnings about excipients at the end of this section). - If you do not have enough immunoglobulins of the type IgA in your blood or have developed antibodies to IgA. - If you have hereditary fructose intolerance, a quite rare genetic condition where the enzyme for breaking down fructose is not produced. Take special care with Flebogamma 10% DIF Certain adverse reactions may occur more frequently: in case of high rate of infusion. if you have hypo- or agammaglobulinaemia (a condition implying low immunoglobulin levels in your blood) with or without IgA deficiency. if you are having Flebogamma 10% DIF for the first time, or it has been switched from an alternative human normal immunoglobulin (IVIg) product, or it is a long time since your last infusion (e.g. several weeks). You will be watched carefully until an hour after the infusion to detect potential adverse signs. Allergic reactions are rare. It may happen particularly if you do not have enough immunoglobulins of the type IgA in your blood or have developed antibodies to IgA. Rarely, human normal immunoglobulin can induce a fall in blood pressure with allergic reaction, even if you had tolerated previous treatment with human normal immunoglobulin. Patient with pre-existing risk factors Please tell your doctor if you have any other condition and/or illness, as caution is required in patients with pre-existing risk factors for clotting (thrombotic) events. In particular, tell your doctor if you have: diabetes high blood pressure history of vascular disease or thrombosis overweight problem blood volume decrease diseases which increase blood viscosity advanced age 2

Patients with a kidney problem In case of kidney problem, your doctor should consider whether to stop treatment since cases of acute renal failure have been reported in patients receiving IVIg therapy, generally in patients with risk factors. Tell your doctor, even when any of the above-mentioned circumstances had happened to you in the past. Special safety warning When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/infections. Manufacturers of these products also include steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This applies to any unknown or emerging viruses or other types of infections. The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A and parvovirus B19 viruses. Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective. It is strongly recommended that every time you receive a dose of Flebogamma 10% DIF the name and batch number of the product are recorded in order to maintain a record of the batches used. Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Effects on vaccines: Flebogamma 10% DIF may reduce the effectiveness of certain type of vaccines such as measles, rubella, mumps and varicella. Effects on blood tests After receiving Flebogamma 10% DIF, the results of certain blood tests (serological tests) may be interfered for a certain time. If you have a blood test after receiving Flebogamma 10% DIF, please tell the analyst or your doctor that you have been given this medicine. 3

Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine. If you are pregnant or breast-feeding you must tell your doctor. Your doctor will decide if Flebogamma 10% DIF can be used during pregnancy and breast-feeding. Driving and using of machines Dizziness can sometimes occur and might affect the ability to drive and use machines. Important information about some of the ingredients of Flebogamma 10% DIF Special warnings about ingredients: This medicine contains 5 g of sorbitol per 100 ml as excipient. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine. You should not use this product if you have fructose intolerance. In babies and young children hereditary fructose intolerance may not yet be diagnosed and may be fatal, thus, they should not receive this medicine. 3. HOW TO USE FLEBOGAMMA 10% DIF Flebogamma 10% DIF is given by injection into your veins (intravenous administration). It may be self administered if you have been fully trained by hospital staff. You must make up the infusion in exactly the way you have been shown in order to stop germs getting in. You must never self administer it alone; a responsible adult must be always present. The dose that you will be given will depend on your illness and body weight and will be worked out by your doctor. At the beginning of your infusion you will receive Flebogamma 10% DIF at a slow rate (0.01 ml/kg/min (1 mg/kg/min)). Depending on how comfortable you feel, your doctor may then gradually increase the infusion rate (up to 0.08 ml/kg/min (8 mg/kg/min)). The solution should be clear or slightly opalescent. Do not use Flebogamma 10% DIF if you notice that the solution is cloudy or has deposits. Flebogamma 10% DIF should not be mixed with other medicines or intravenous solutions and it should be administered by a separate intravenous line. Use in children The dose in children is not considered to be different to that of adults as it will be given depending on the illness and body weight of the children. If you use more Flebogamma 10% DIF than you should 4

If you are given more Flebogamma 10% DIF than you should, your body may take on too much fluid. You may have fatigue, difficult breathing, swelling in the legs and arms, increase in weight or sleeping difficulties. This could particularly happen when you are a patient at risk, e.g. an elderly patient or a patient having problems with your kidneys. Tell your doctor or pharmacist immediately. Contact poisons information centre on 131126 for advice on management. If you forget to use Flebogamma 10% DIF Tell your doctor or pharmacist immediately and follow his/her instructions. You must not be given a double dose to make up for a forgotten dose. 4. POSSIBLE SIDE EFFECTS Like all medicines, Flebogamma 10% DIF can cause side effects, although not everybody gets them. In rare and isolated cases, the following side effects have been reported with immunoglobulin preparations. Tell your doctor if any of the following side effects happen during or after the infusion: Allergic reactions and isolated cases of anaphylactic shock, even if you have shown no hypersensitivity to previous administration. Cases of temporary meningitis (reversible aseptic meningitis) Cases of temporary reduction in the number of the red cells in the blood (reversible haemolytic anaemia/haemolysis) Cases of transient cutaneous reactions Increase in serum creatinine level and/or acute renal failure. Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses. Three clinical studies with Flebogamma 10% DIF were conducted. In these studies different side effects have been observed. These side effects and frequency are detailed below using the following convention: - very common (affects more than 1 user in 10) - common (affects 1 to 10 users in 100) - uncommon (affects 1 to 10 users in 1,000) - rare (affects 1 to 10 users in 10,000) - very rare (affects less than 1 user in 10,000) - not known (frequency cannot be estimated from the available data) Very common: headache nausea fever (body temperature increased) 5

Common: red blood cells and white blood cells decreased heart rate increase or tachycardia (acceleration of the heart activity) cyanosis vertigo photophobia (excessive sensitivity to light) abdominal pain (including abdominal pain upper) diarrhoea vomiting infusion related reaction and infusion site reaction infusion site pain pain rigors (cold shivering sensation) tremor/chills (to tremble) influenza like illness chest discomfort feeling cold edema peripheral (swelling of extremities due to the accumulation of fluids) blood pressure decrease blood pressure increase haemoglobin decreased (haemoglobin is a substance in the blood which carries oxygen) anorexia (lack of appetite) myalgia (muscle pain) muscle tightness back pain dizziness (motion sickness) radicular syndrome (neck or back pain and other symptoms such as numbness, tingling and weakness in the arms or legs) epistaxis ecchymosis (large skin hematoma) erythema (redness of the skin) pruritus (itching) rash (eruption of the skin) flushing (to blush) thrombosis Uncommon: ear pain conjunctivitis (inflammation of the conjuntiva of the eyes) maculopathy (illness of the macula, in the retina of the eyes) abdominal distension flatulence chest pain fatigue feeling jittery (nervousness) infusion site erythema (redness in the area of injection) 6

malaise influenza (flu) urinary infection arthralgia (joint pain) muscle spasms neck pain pain in extremities syncope vasovagal (fainting) postnasal drip (excessive mucus) sinus pain wheezing acne haematoma If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 5. HOW TO STORE FLEBOGAMMA 10% DIF Keep out of the reach and sight of children. Do not use Flebogamma 10% DIF after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Store below 30 ºC. Do not freeze. Protect form light. The product should be brought to room or body temperature before use. The solution should be clear or slightly opalescent. Do not use Flebogamma 10% DIF if you notice that the solution is cloudy or has deposits. Any unused product or waste material should be disposed of in accordance with local requirements. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. 6. FURTHER INFORMATION What Flebogamma 10% DIF contains - The active substance is human normal immunoglobulin (IVIg). One ml contains 100 mg of human normal immunoglobulin, of which at least 97% is IgG. One vial of 50 ml contains: 5 g of human normal immunoglobulin One vial of 100 ml contains: 10 g of human normal immunoglobulin One vial of 200 ml contains: 20 g of human normal immunoglobulin 7

The percentage of IgG subclasses is approximately 66.6% IgG1, 27.9% IgG2, 3.0% IgG3 and 2.5% IgG4.Contains trace amounts of IgA (lower than 100 micrograms/ml). - The other ingredients are 5% sorbitol and water for injection. (see section 2 for further information about ingredients). What Flebogamma 10% DIF looks like and contents of the pack Flebogamma 10% DIF is a solution for infusion. The solution is clear or slightly opalescent and colourless or pale yellow. Flebogamma 10% DIF is supplied as: 5 g/50 ml AUST R 184353 10 g/100 ml AUST R 182358 20 g/200 ml AUST R 182359 Pack size of 1 vial. Not all sizes may be marketed. Marketing authorisation holder and manufacturer Instituto Grifols, S.A. Can Guasch, 2 - Parets del Vallès 08150 Barcelona - SPAIN Imported and distributed by: Grifols Australia Pty Ltd 5/80 Fairbank Road, Clayton South, Victoria, Australia 3169 This leaflet was last approved in January 2013 8